Boston Therapeutics, Inc. announced the additions of Dr. Harold S. Parnes and Dr. Robert Silverman, MD round out the expertise of the new Scientific Advisory Board enabling the company to launch new strategic initiatives in 2018. Harold S. Parnes, MD, FACR is a strong supporter of SUGARDOWN non-systemic treatment for glucose intolerance, valuing it as an alterative to other treatments that can lead to hypoglycemia if not managed properly. He is currently Chairman of the Board of Trustees, Alumni Association College of Medicine, State University of NY, Downstate Medical Center, Former Director of Neuroradiology, Dept of Radiology, Queens Hospital Center, and President and Medical Director of Omega Diagnostic Imaging. Dr. Parnes adds important expertise to the company's understanding of how metabolic defects of diabetes affects neurobiology. As the company explores new therapeutic opportunities in the area of oxygen perfusion and neurobiology, Dr. Parnes will be an invaluable resource. Robert Silverman, MD, FACE has helped gain FDA approval for a long list of therapeutic candidates. A Former Merck Research Laboratories (MRL) Executive Director of Global Regulatory Strategy, Policy and Safety, Former NIH, Chief, Diabetes Programs Branch, Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK, and Former Scientific Officer of the seminal Diabetes Control and Complications Trial (DCCT), Dr. Silverman is an expert in FDA regulatory strategies. As the company continues to reach clinical milestones and achieve commercialization, Dr. Silverman’s experience will help the team to most efficiently navigate the regulatory process.